Equine Performance Labs Market Research Report

Background

Company Overview

Equine Performance Labs (EPL) is a biotechnology company specializing in regenerative therapies for equine health. Founded in 2022 and headquartered in Austin, Texas, EPL focuses on developing advanced products to aid in the healing, recovery, and performance enhancement of horses. The company's mission is "Horse First, Sport Second," emphasizing the well-being of equine athletes. EPL's flagship product, equicent™ CTM, is an injectable allograft derived from equine umbilical cord tissue, designed for musculoskeletal repair.

Key Strategic Focus

Core Objectives

EPL aims to revolutionize equine regenerative medicine by providing innovative, biologically-based solutions that promote natural healing and enhance performance. The company is committed to advancing equine health through scientific research and development.

Areas of Specialization

EPL specializes in regenerative therapies, focusing on musculoskeletal repair, tissue regeneration, and performance enhancement in horses.

Key Technologies Utilized

The company employs proprietary tissue processing techniques and utilizes cryopreserved equine umbilical cord tissue to create its allograft products. This approach ensures consistency and safety in their offerings.

Primary Markets Targeted

EPL targets the equine veterinary market, specifically focusing on racehorses, performance horses, and other equine athletes requiring advanced regenerative treatments.

Financials and Funding

Funding History

As of March 2026, specific details regarding EPL's total funds raised and recent funding rounds are not publicly disclosed. The company has not publicly announced any funding events or investors.

Utilization of Capital

While specific utilization details are not available, it is likely that any raised capital would be directed towards research and development, product manufacturing, and market expansion efforts.

Pipeline Development

Key Pipeline Candidates

EPL's primary product, equicent™ CTM, is an injectable allograft derived from equine umbilical cord tissue, designed for musculoskeletal repair. The company has published a peer-reviewed study demonstrating the safety, consistency, and clinical promise of this product.

Stages of Development

equicent™ CTM has undergone controlled, randomized, in vivo evaluations, confirming its safety and efficacy for intra-articular and intralesional use in horses. The product is currently available for clinical use.

Target Conditions

The product is intended for the repair and regeneration of equine musculoskeletal tissues, including joints, tendons, and ligaments.

Anticipated Milestones

EPL continues to monitor the clinical outcomes of equicent™ CTM, aiming to expand its applications and further validate its effectiveness in various equine populations.

Technological Platform and Innovation

Proprietary Technologies

EPL's proprietary technology involves the processing of equine umbilical cord tissue to create a cryopreserved, micro-particulate allograft. This method ensures a consistent and high-quality product for equine musculoskeletal repair.

Significant Scientific Methods

The company employs advanced tissue processing techniques and conducts rigorous in vivo studies to assess the safety and efficacy of its products. The recent publication in BMC Medicine highlights the scientific rigor behind EPL's offerings.

Leadership Team

Key Executives

Heather Rogers: Chief Executive Officer. Heather has a background in equine veterinary medicine and has been instrumental in leading EPL's strategic direction and product development.

Maren Rosen: Chief Marketing Officer. Maren oversees EPL's marketing strategies, focusing on brand development and market outreach.

Gary Monteiro: Chief Product Officer. Gary leads product development initiatives, ensuring the scientific integrity and clinical relevance of EPL's offerings.

Megan Smith: Director of Business Development. Megan is responsible for identifying and pursuing strategic partnerships and business opportunities to expand EPL's market presence.

Abraham Silfen: Director of Quality. Abraham ensures that EPL's products meet the highest standards of quality and safety through rigorous testing and quality control processes.

Competitor Profile

Market Insights and Dynamics

The equine regenerative medicine market is experiencing growth, driven by advancements in biologics and increasing demand for non-invasive treatments. Key trends include a focus on natural healing processes and the development of products that minimize recovery times for equine athletes.

Competitor Analysis

EPL operates in a competitive landscape with several notable companies:

Astaria Global: Acquired by Creative Science in April 2025, Astaria Global developed biological anti-inflammatory solutions for the equine industry, including Alpha2EQ, a treatment utilizing the horse's own blood to deliver anti-inflammatory effects.

Exceed Equine: A company focused on developing and distributing cutting-edge products and services for performance horses, aiming to become the most trusted brand in the equine performance market.

NIVO: Based in Copenhagen, NIVO develops wearable saddle sensors to monitor horse training data, providing insights into equine performance.

Strategic Collaborations and Partnerships

EPL has not publicly disclosed any strategic collaborations or partnerships as of March 2026.

Operational Insights

Strategic Considerations

EPL's focus on biologically-based regenerative therapies positions it uniquely in the equine health market. The company's commitment to scientific research and product consistency provides a competitive edge in offering effective solutions for equine musculoskeletal issues.

Strategic Opportunities and Future Directions

Roadmap and Expansion

EPL plans to expand its product line by developing additional regenerative therapies targeting various equine health concerns. The company aims to strengthen its market presence through strategic partnerships and by leveraging its scientific expertise to introduce innovative solutions.